IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity

被引:58
作者
Cryns, Kim [1 ]
Shamir, Alon [2 ,3 ]
Van Acker, Nathalie [4 ]
Levi, Itzhak [2 ,3 ]
Daneels, Guy [1 ]
Goris, Ilse [1 ]
Bouwknecht, J. Adriaan [1 ]
Andries, Luc [4 ]
Kass, Stefan [1 ]
Agam, Galila [2 ,3 ]
Belmaker, Haim [2 ,3 ]
Bersudsky, Yuly [2 ,3 ]
Steckler, Thomas [1 ]
Moechars, Dieder [1 ]
机构
[1] Johnson & Johnson Pharmaceut Res & Dev, Res & Early Dev Europe, B-2340 Beerse, Belgium
[2] Ben Gurion Univ Negev, Fac Hlth Sci, Stanley Res Ctr, IL-84105 Beer Sheva, Israel
[3] Mental Hlth Ctr, Beer Sheva, Israel
[4] Histogenex, Antwerp, Belgium
关键词
IMPA1; lithium; bipolar disorder; pilocarpine; IMPase activity; inositol;
D O I
10.1038/sj.npp.1301431
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Lithium has been the standard pharmacological treatment for bipolar disorder over the last 50 years; however, the molecular targets through which lithium exerts its therapeutic effects are still not defined. We characterized the phenotype of mice with a dysfunctional IMPA1 gene (IMPA1(-/-)) to study the in vivo physiological functions of IMPA1, in general, and more specifically its potential role as a molecular target in mediating lithium-dependent physiological effects. Homozygote IMPA1(-/-) mice died in utero between days 9.5 and 10.5 post coitum (p. c.) demonstrating the importance of IMPA1 in early embryonic development. Intriguingly, the embryonic lethality could be reversed by myo-inositol supplementation via the pregnant mothers. In brains of adult IMPA1(-/-) mice, IMPase activity levels were found to be reduced ( up to 65% in hippocampus); however, inositol levels were not found to be altered. Behavioral analysis of the IMPA1(-/-) mice indicated an increased motor activity in both the open-field test and the forced-swim test as well as a strongly increased sensitivity to pilocarpine-induced seizures, the latter supporting the idea that IMPA1 represents a physiologically relevant target for lithium. In conclusion the IMPA1(-/-) mouse represents a novel model to study inositol homeostasis, and indicates that genetic inactivation of IMPA1 can mimic some actions of lithium.
引用
收藏
页码:674 / 684
页数:11
相关论文
共 43 条
[1]   Myo-inositol-1-phosphate (MIP) synthase:: a possible new target for antibipolar drugs [J].
Agam, G ;
Shamir, A ;
Shaltiel, G ;
Greenberg, ML .
BIPOLAR DISORDERS, 2002, 4 :15-20
[2]   REDUCED BRAIN INOSITOL IN LITHIUM-TREATED RATS [J].
ALLISON, JH ;
STEWART, MA .
NATURE-NEW BIOLOGY, 1971, 233 (43) :267-&
[3]   INCREASED BRAIN MYOINOSITOL 1-PHOSPHATE IN LITHIUM-TREATED RATS [J].
ALLISON, JH ;
BLISNER, ME ;
HOLLAND, WH ;
HIPPS, PP ;
SHERMAN, WR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1976, 71 (02) :664-670
[4]   INOSITOL MONOPHOSPHATASE - A PUTATIVE TARGET FOR LI+ IN THE TREATMENT OF BIPOLAR DISORDER [J].
ATACK, JR ;
BROUGHTON, HB ;
POLLACK, SJ .
TRENDS IN NEUROSCIENCES, 1995, 18 (08) :343-349
[5]   THE INHIBITION OF PHOSPHOINOSITIDE SYNTHESIS AND MUSCARINIC-RECEPTOR-MEDIATED PHOSPHOLIPASE-C ACTIVITY BY LI+ AS SECONDARY, SELECTIVE, CONSEQUENCES OF INOSITOL DEPLETION IN 1321N1 CELLS [J].
BATTY, IH ;
DOWNES, CP .
BIOCHEMICAL JOURNAL, 1994, 297 :529-537
[6]   CHROMOSOME-18 DNA MARKERS AND MANIC-DEPRESSIVE ILLNESS - EVIDENCE FOR A SUSCEPTIBILITY GENE [J].
BERRETTINI, WH ;
FERRARO, TN ;
GOLDIN, LR ;
WEEKS, DE ;
DETERAWADLEIGH, S ;
NURNBERGER, JI ;
GERSHON, ES .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (13) :5918-5921
[7]   INOSITOL PHOSPHATES AND CELL SIGNALING [J].
BERRIDGE, MJ ;
IRVINE, RF .
NATURE, 1989, 341 (6239) :197-205
[8]   NEURAL AND DEVELOPMENTAL ACTIONS OF LITHIUM - A UNIFYING HYPOTHESIS [J].
BERRIDGE, MJ ;
DOWNES, CP ;
HANLEY, MR .
CELL, 1989, 59 (03) :411-419
[9]   LITHIUM AMPLIFIES AGONIST-DEPENDENT PHOSPHATIDYLINOSITOL RESPONSES IN BRAIN AND SALIVARY-GLANDS [J].
BERRIDGE, MJ ;
DOWNES, CP ;
HANLEY, MR .
BIOCHEMICAL JOURNAL, 1982, 206 (03) :587-595
[10]   BEHAVIORAL EVIDENCE FOR THE EXISTENCE OF 2 POOLS OF CELLULAR INOSITOL [J].
BERSUDSKY, Y ;
KAPLAN, Z ;
SHAPIRO, Y ;
AGAM, G ;
KOFMAN, O ;
BELMAKER, RH .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1994, 4 (04) :463-467